Video
Pembrolizumab for BCG-unresponsive high-risk NMIBC: Considerations for use
Author(s):
Arjun V. Balar, MD, walks through the patient discussion when weighing the use of pembrolizumab (Keytruda).
Video Player is loading.
In this video, Arjun V. Balar, MD, explains what a urologist should look for or consider regarding tumor and patient characteristics when deciding on use of pembrolizumab in patients with BCG-unresponsive, high-risk non–muscle invasive bladder cancer. Balar is associate professor of medicine at the NYU Grossman School of Medicine and genitourinary medical oncology program director at NYU Langone’s Perlmutter Cancer Center, New York.
Related Videos
5 key trial insights from AUA 2025
Shreyas Joshi, MD, recaps AUA session on chemotherapy vs novel NMIBC options
Shay Rajavel, MS3, on CO2 gas embolism during single-port partial nephrectomy
Kevin Zorn, MD, on preserving ejaculation with BPH therapies
Neal Shore, MD, on sasanlimab plus BCG for BCG-naïve NMIBC
Alexander Glaser, MD, on real-world outcomes with Aquablation
Vitaly Margulis, MD, on preliminary safety, efficacy of padeliporfin VTP for UTUC
Joseph Jacob, MD, on the durability of TAR-200 in NMIBC
Margaret Knoedler, MD, on Ho:YAG vs thulium fiber laser for ureteroscopy
John Gore, MD, on radical cystectomy vs bladder-sparing therapy for NMIBC
Related Content
